secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0001193125-23-252984
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Pharma announces last patient last visit in pivotal STRIDE study; topline data expected Dec 2023
--------------------------------------------------------------------------------

- Last patient last visit completed in STRIDE study of mavodelpar for primary mitochondrial myopathies; topline data expected December 2023.
- Over 85% of eligible patients enrolled in ongoing STRIDE AHEAD study.
- Company to share data analysis with FDA in Q1 2024; NDA submission planned first half 2024.
- STRIDE and STRIDE AHEAD studies to form basis of NDA submission to FDA and other regulators.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312523252984/0001193125-23-252984-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312523252984/d535917d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-252984

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer